BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased...